Zai Lab Raises $261 Million; Plans China NDA Filing for Ripretinib in Mid-2020
publication date: Jan 24, 2020
Zai Lab, a Shanghai novel commercial stage biopharma, raised $261 million in a secondary offering. The company reported it held $68.7 million of cash on September 30, 2019 and spent $110 million on R&D in the first nine months of last year, a near-doubling from 2018 due to new projects and ongoing clinical trials. Zai also announced it expects to submit a China NDA for ripretinib by mid-2020 to treat gastrointestinal stromal tumors. In late December, Zai reported China approval for Zezula, a PARP inhibitor and Zai's first drug to launch in China. More details....
Stock Symbol: (NSDQ: ZLAB)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.